Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa
This cohort study evaluates the risk of developing inflammatory arthritis among patients with hidradenitis suppurativa.
Patients with hidradenitis suppurativa (HS) face an increased risk of developing inflammatory arthritis, according to findings from a claims database.Reuters Health Information
NEW YORK (Reuters Health)—Patients with hidradenitis suppurativa face an increased risk of developing inflammatory arthritis, according to findings from a claims database. “We observed increased risks of developing ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (RA) among patients with hidradenitis suppurativa when compared with those without hidradenitis suppurativa,” says Maria C. Schneeweiss, MD, of Brigham... [Read More]
Conclusion: We report the “real-life” use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition.
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice. The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable molecules. Multiple cytokine receptors signal through Janus kinases (JAKs) and associated signal transducer and activato...
ConclusionThe safety profile of adalimumab was consistent with previous findings and no new safety signals were observed.
Background: Psoriasis, psoriatic arthritis, atopic dermatitis (AD), hidradenitis suppurativa (HS) and chronic urticaria (CU) are associated with sleep disturbances (SD). Validated, disease-specific instruments are needed to assess SD in these populations. This work focuses on the development of the ‘PsO Sleepy-Q’ for psoriasis and ‘PsA Sleepy-Q’ for psoriatic arthritis.
There is a dearth of high-level evidence guiding our understanding of the epidemiology, pathophysiology, and treatment of hidradenitis suppurativa (HS). Despite an estimated prevalence of 1% in Western populations and quality of life impairment often exceeding other chronic skin diseases, annual HS-related publications lag far behind annual publications for other common and rare skin diseases (Figure, A). Federal funding to study HS wanes in comparison to funding for other chronic cutaneous dermatoses, with only 0.1% of the National Institute of Arthritis and Musculoskeletal and Skin Diseases total research funds for skin ...
CONCLUSION: We report a case of IGM associated with erythema nodosum. Dermatologists must be aware of this association. PMID: 31151772 [PubMed - as supplied by publisher]
ConclusionsThis study demonstrates that the risk of developing a second IMID is significantly higher for individuals who have already experienced a first IMID in a large and contemporary US claims database. Certain pairs of IMIDs co-occur more frequently than others. The risk of developing subsequent IMIDs may be an important consideration for clinicians when selecting treatment strategies.FundingAbbvie.
Conclusions In this review, we collected all the information concerning the OMICs studies performed on HS patients aimed at unraveling the mechanisms at the basis of the disease or associated to clinical severity and/or the successful response to pharmacological treatment (including biological drugs). The general picture of the OMICs contribution in the context of HS is not so clear and/or rich of clinical useful information, since most of the studies focused only on one aspect (genome, transcriptome, or proteome) of the disease, enrolling small numbers of patients (this is quite limiting for the genetic studies) from di...